The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kawanishi, C.
* Articles by Kosaka, K.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Kawanishi, C.
* Articles by Kosaka, K.
Related Collections
* Schizophrenia Spectrum Disorders
* Other Neuroleptics
* Genetics
Am J Psychiatry 155:1275-1277, September 1998
©Copyright 1998 American Psychiatric Association


Brief Report

Lack of Association Between Neuroleptic Malignant Syndrome and Polymorphisms in the 5-HT1A and 5-HT2A Receptor Genes

Chiaki Kawanishi, M.D., Ph.D., Tokiji Hanihara, M.D., Yoshikazu Shimoda, M.D., Kyoko Suzuki, Ph.D., Naoya Sugiyama, M.D., Ph.D., Hideki Onishi, M.D., Ph.D., Tomohiro Miyakawa, M.D., Yoshiteru Yamada, M.D., Ph.D., and Kenji Kosaka, M.D., Ph.D.

Objective: The molecular basis of neuroleptic malignant syndrome is unclear, but studies suggest that genetic factors are involved in its pathogenesis. Considering possible involvement of the serotonergic system in neuroleptic malignant syndrome, the authors examined the association between neuroleptic malignant syndrome and polymorphisms of the 5-HT1A and 5-HT2A receptor genes.Method: The authors examined the frequencies of gene polymorphisms in the 5-HT1A (Arg219Leu) and 5-HT2A (Thr25Asn and His452Tyr) receptor genes in 29 patients previously diagnosed with neuroleptic malignant syndrome, 94 neuroleptic-treated patients with schizophrenia who had no history of neuroleptic malignant syndrome, and 94 healthy comparison subjects. Polymerase chain reaction and restriction fragment length polymorphism analyses were used to screen gene mutations.Results: No polymorphic allele was detected in the patients who had experienced the neuroleptic malignant syndrome. Conclusions: The authors cannot conclude that polymorphisms in the 5-HT1A and 5HT2A receptor genes are factors determining susceptibility to the neuroleptic malignant syndrome. Am J Psychiatry 1998; 155: 1275-1277




This article has been cited by other articles:


Home page
Br J AnaesthHome page
P. Adnet, P. Lestavel, and R. Krivosic-Horber
Neuroleptic malignant syndrome
Br. J. Anaesth., July 1, 2000; 85(1): 129 - 135.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org